Cargando…
Antibody-drug conjugates: Present and future
Antibody-drug conjugates (ADCs) are becoming an increasingly important sub-class of antibody-related therapeutics. Two ADCs, brentuximab vedotin (Adcetris®) and ado-trastuzumab emtansine (Kadcyla®), were recently approved for marketing both by the US Food and Drug Administration (FDA) and the Europe...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098595/ https://www.ncbi.nlm.nih.gov/pubmed/24423577 http://dx.doi.org/10.4161/mabs.27436 |